The deal is part of BioReference's ongoing effort to streamline its business to achieve profitability and follows the sale last year of clinical laboratory assets to Labcorp.

Phillip Frost; Chairman of the Board, Chief Executive Officer; OPKO Health Inc Elias Zerhouni; President, Vice Chairman of the Board; OPKO Health Inc Good day. And welcome to the OPKO Health fourth ...

Q4 2024 Earnings Conference Call February 27, 2025 4:30 PM ETCompany ParticipantsYvonne Briggs - Alliance Advisors IRDr.

The new acquisitions, Bioverativ and Ablynx, are also part of the growth plan, and Brandicourt and R&D head Elias Zerhouni explained some of the potential benefits of their multi-billion euro outlays.

The deal comes just a few months after Opko acquired ModeX – which was set up by former Sanofi R&D veterans Elias Zerhouni and Gary Nabel in 2020 – for $300 million in stock. The company was ...